Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
19.43
+0.26 (1.36%)
At close: Dec 15, 2025, 4:00 PM EST
19.10
-0.33 (-1.70%)
After-hours: Dec 15, 2025, 7:48 PM EST
Simulations Plus Revenue
In the fiscal year ending August 31, 2025, Simulations Plus had annual revenue of $79.18M with 13.09% growth. Simulations Plus had revenue of $17.46M in the quarter ending August 31, 2025, a decrease of -6.45%.
Revenue (ttm)
$79.18M
Revenue Growth
+13.09%
P/S Ratio
4.93
Revenue / Employee
$371,732
Employees
213
Market Cap
391.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 79.18M | 9.17M | 13.09% |
| Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
| Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
| Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
| Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
| Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
| Aug 31, 2019 | 33.97M | 4.30M | 14.51% |
| Aug 31, 2018 | 29.67M | 5.53M | 22.90% |
| Aug 31, 2017 | 24.14M | 4.17M | 20.86% |
| Aug 31, 2016 | 19.97M | 1.66M | 9.05% |
| Aug 31, 2015 | 18.31M | 6.85M | 59.80% |
| Aug 31, 2014 | 11.46M | 1.39M | 13.80% |
| Aug 31, 2013 | 10.07M | 622.16K | 6.58% |
| Aug 31, 2012 | 9.45M | 709.87K | 8.12% |
| Aug 31, 2011 | 8.74M | -1.97M | -18.42% |
| Aug 31, 2010 | 10.71M | 1.57M | 17.16% |
| Aug 31, 2009 | 9.14M | 175.30K | 1.95% |
| Aug 31, 2008 | 8.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLP News
- 6 days ago - Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions - Business Wire
- 11 days ago - Why Shares of Simulations Plus Soared This Week - The Motley Fool
- 13 days ago - Simulations Plus: Buying On Long-Term Silico Drug-Development - Seeking Alpha
- 13 days ago - Why Simulations Plus Stock Was Soaring Today - The Motley Fool
- 13 days ago - Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound - Benzinga
- 14 days ago - Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results - Business Wire
- 6 weeks ago - SIMULATIONS PLUS INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Simulations Plus Investors to Contact the Firm Regarding Their Rights - GlobeNewsWire